Replies to post #2151 on CTI BioPharma Corp (fka CTIC)

[Lindy]

His timing is malicious and looks like he was short. I hope the CEO files a complaint and he is investigated and proven wrong.

[foggdogg]

CTI's Response to Foolstein:

Cell Therapeutics says:
June 1, 2009 at 6:59 pm
It is amazing to us at CTI how a self-proclaimed expert in biotech research, Adam Feuertsein can pass advice on to readers/clients regarding clinical trial results when that individual has neither a clinical background nor a medical degree. Second, and most importantly, the analyst didn’t even bother to attend ASCO and listen to the interested feedback from physicians and responses from the principal investigator on the PIX301 Extend trial. Had he done so he may have actually learned something about why these results are so important and as Dr. Ruth Pettengal noted, represent a breakthrough in the treatment of patients with relapsed aggressive NHL.

The presentation of the PIX301 results was among the most crowded, well attended sessions, underscoring the interest about the compound and the data. In the general oral session following the presentation, PIX301 was reviewed by an expert medical doctor appointed by ASCO to discuss the highlights of that session. The doctor began the session by noting that there are no approved agents for relapsed or refractory aggressive NHL, and that an overall response rate of 30% would be a success for this unmet medical need. He then went on to describe how pixantrone was rationally designed to remove the substitutions responsible for free radical generation, thus allowing anthracyclines to be re-introduced into a disease setting where, due to cardiac toxicity concerns, they are not typically used. The doctor focused on the high overall response rate, the duration of CR being almost twice as long as with standard chemotherapy and notably the overall lack of significant cardiac events despite the high degree of prior anthracycline exposure. He concluded that the promising results was the first randomized study to demonstrate high and durable rates of response in this unmet medical need.

It would be worthwhile to refer Mr. Feuerstein to your (Iguana Biotech’s) research notes and the information on the background incidence of cardiac events. That way rather than making assumption regarding missing numbers, he can be educated. Clearly the thought leader discussant and the PI were impressed with the data. Maybe, just maybe, they may know more than a political science major like Mr. Feuerstein—Cell Therapeutics